Following his recent publication in the Lancet Respiratory Medicine, and presentation at the ERS Congress, we spoke with Prof. Liam Heaney (Queen’s University, Belfast, Northern Ireland, UK) about the composite biomarker approach to optimising steroid dosage in patients with severe asthma.
- Why is there a need for new approaches to optimising steroid dosage in people with severe asthma? (0:11)
- Could you give us a brief overview of the composite biomarker approach to optimising steroid dosage? (1:06)
- Could you tell us a little about your recent study comparing this approach with a symptomatic/risk/based algorithm? (2:23)
- What were the major findings of this study in terms of clinical and patient-reported outcomes? (4:19)
- What will be the impact of these findings on clinical practice and what future studies are planned? (6:10)
Speaker disclosure: Liam Heaney has received grant funding and taken part in advisory boards and given lectures at meetings supported by Hoffmann-La Roche–Genentech and Aerocrine. He has also taken part in asthma clinical trials sponsored by Hoffmann-La Roche–Genentech, and is an Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma, which involves industrial partnerships with a number of pharmaceutical companies, including Hoffman-La Roche and Aerocrine.
Support: Interview and filming supported by Touch Medical Media. Niche Science and Technology were given the opportunity to review the video. No changes to the video were made as a result.
Filmed in coverage of the ERS International Congress 2020.
Share this Video
Related Videos In Asthma
Whitney Stevens, AAAAI 2021: Treatment of Aspirin-Exacerbated Respiratory Disease (AERD)
It was a pleasure to speak with Professor Whitney Stevens (Northwestern University Feinberg School of Medicine, Chicago, IL, US) around aspirin desensitisation in aspirin-exacerbated respiratory disease. ‘Aspirin desensitization for AERD in 2020: An update from the AERD work group.’ was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March […]
Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 2)
Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) spoke with touchRESPIRATORY around his post-hoc analysis of the LIBERTY ASTHMA QUEST study (Clinical Trial Identifier: NCT02414854). The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American […]
Klaus Rabe, AAAAI 2021 – The Efficacy of Dupilumab in GINA-Defined Difficult To-Treat Type 2 Asthma Patients (Part 1)
It was a pleasure to speak with Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) around the rationale for the use of dupilumab in GINA-defined difficult to-treat type 2 asthma patients (Clinical Trial Identifier: NCT02414854). The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!